NCT06046417View on ClinicalTrials.gov

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
type1diabetesDiabetes Mellitus, Type 1
Interventions
DRUG

Pramlintide

Pramlintide delivered in a basal-bolus manner.

DRUG

Lyumjev

Lyumjev delivered in a basal-bolus manner.

DEVICE

Automated Insulin Delivery (AID) system

The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.

Trial Locations (1)

H4A 3J1

RECRUITING

Research Institute of the McGill University Health Center, Montreal

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER